d4T (Stavudine, Zerit): News
- d4T -- Time to Move On (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Blog Examines Use of Controversial HIV Drug in Malawi (August 16, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Stavudine (d4T) Phase-Out Festival in Delhi (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Activists Oppose Gates Foundation Funding Study Using Low-Dose d4T (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Why It's Time to Say Goodbye to Stavudine ... Everywhere (2012)
A group of prominent HIV/AIDS activists and experts argue against any attempt to encourage greater use of Zerit (stavudine).
In Southern African Journal of HIV Medicine
- European Medicines Agency Issues Restricted Indication for d4T (Stavudine) (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- New Labeling for Zerit Capsules and Zerit for Oral Solution (December 10, 2010)
From U.S. Food and Drug Administration
- New WHO Guidelines Urge Phase-Out of Major HIV Drug (December 1, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Approval of Three Generic Stavudine Formulations (December 30, 2008)
From U.S. Food and Drug Administration
- Drop d4T From First-Line Therapy, WHO Advises Low-Income Countries – If You Can Afford To (August 8, 2006)
- FDA Tentatively Approves Generic Pediatric d4T for PEPFAR (December 22, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Efavirenz, Stavudine Demand May Soon Exceed Supply in Developing World (March 4, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- South African Generic Drug Maker to Produce Country's First Generic Antiretroviral Drug (August 7, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- It's Time to Face the Zerit Problem (March 2003)
Nelson Vergel urges Bristol-Myers Squibb to do more to minimize the lipoatrophy effects of d4T (stavudine, Zerit), and recommends it no longer be used as first-line treatment in the meantime.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- FDA Approves Zerit Once Daily, Extended Release Formulation (January 10, 2003)
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project
- Zerit XR Enters the Home Stretch (December 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Fatal d4T Lactic Acidosis Spurs New Label Warning (Summer/Autumn 2002)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- d4T and Lactic Acidosis With Neuromuscular Weakness: FDA Warning (March 8, 2002)
In AIDS Treatment News, from AIDS Treatment News
- Changes in Zerit Product Labeling Reflect Potential Safety Concerns (February 2002)
From U.S. Food and Drug Administration
- FDA/Bristol Myers Squibb Issues Caution for HIV Combination Therapy With Zerit and Videx in Pregnant Women (January 5, 2001)
From U.S. Food and Drug Administration
- ddI, d4T and Hydroxyurea Side Effect Warning! (April 2000)
In Project Inform Perspective, from Project Inform
|
Advertisement
|
Email
Glossary
